Company news

Femasys Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Femasys Appoints John Moorhead to Board of Directors

October 30, 2026

Femasys Partners with SandsRx Pharmacy to Support FemaSeed® Fertility Portfolio Launch to OB/GYNs

October 20, 2026

Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control

October 14, 2026

Femasys to Exhibit at the ASRM 2026 Scientific Congress & Expo

October 8, 2026

Femasys Advances OB/GYN Expansion with Adoption of FemaSeed® Fertility Portfolio by Minnesota Women’s Care

September 15, 2026

Femasys Partners with CapexMD to Expand Patient Access to FemaSeed® Fertility Portfolio

September 9, 2026

Femasys Partners with UNC Health to Introduce Its FemaSeed® Fertility Portfolio Across Statewide OB/GYN Care Locations

August 26, 2026

Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®

August 19, 2026

Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update

August 14, 2026

Femasys Strengthens and Extends Global Patent Protection for FemBloc® with First Issued Blended Polymer Patents

August 12, 2026

Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 Million

August 7, 2026

Femasys Regains Compliance with Nasdaq Listing Requirements

June 23, 2026

Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter

May 13, 2026

Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update

May 8, 2026

Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete

May 5, 2026

Femasys Launches FemaSeed® Complete for OB/GYNs at ACOG 2026

April 22, 2026

Femasys Drives International Growth with Israeli Market Entry for Fertility Portfolio

April 16, 2026

Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth

March 31, 2026

Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update

March 30, 2026

Femasys Appoints Dr. Kenneth D. Eichenbaum to Board of Directors

March 17, 2026

Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment

March 10, 2026

Femasys Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 27, 2026

Femasys Announces FemBloc® Permanent Birth Control Has Achieved MDSAP Certification, Advancing Global Market Access

February 25, 2026

Femasys Receives AMA CPT Editorial Panel Approval for New Category III CPT Code for FemaSeed Intratubal Insemination

February 22, 2026

Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products

February 3, 2026

Femasys Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

January 14, 2026

Femasys Announces Partnership with Refuah Health Center to Expand First-Line Access to FemaSeed® in Community-Based Care

January 13, 2026

Femasys Secures U.S. FDA Clearance for Next-Generation FemVue Diagnostic Device

December 18, 2025

Femasys Announces Third Quarter Financial Results for 2025

November 14, 2025

Femasys Advances Global Growth with Second Partner Order for FemBloc® in Europe

November 10, 2025

Femasys Secures FDA Approval to Advance Final FemBloc® Trial Phase and $12 Million Financing, with Potential to Reach $58 Million

November 3, 2025

Femasys Announces Initiation of Post-Market Surveillance Study for FemBloc® Permanent Birth Control in Europe

October 22, 2025

Femasys to Exhibit at the ASRM 2025 Scientific Congress & Expo

October 16, 2025

Femasys Accelerates European Growth for FemBloc® with Kebomed Partnership

September 25, 2025

Femasys Partners with Medical Electronic Systems to Launch FemSperm™ Analysis Kit for use with FemaSeed

September 22, 2025

Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®

September 11, 2025

Femasys Secures Regulatory Approval for FemBloc® Permanent Birth Control in New Zealand

September 8, 2025

Femasys Closes $8 Million in Financing to Accelerate Commercialization of Fertility and Birth Control Portfolios

September 2, 2025

Femasys Announces Pricing of $8.0 Million Underwritten Public Offering

August 25, 2025

Femasys Announces FemSperm™ Kit to Activate Gynecologists and Advance FemaSeed® Fertility Platform

August 21, 2025

Femasys Secures UK Regulatory Approval of FemBloc Permanent Birth Control

August 20, 2025

Femasys Announces Second Quarter Financial Results for 2025

August 8, 2025

Femasys Secures First European Order for FemBloc, Marking Strategic Milestone in Global Expansion

August 6, 2025

Femasys Achieves Australian and New Zealand Regulatory Approvals for FemaSeed® for First-Line Infertility Treatment and FemVue Diagnostic

July 1, 2025

Femasys Announces Historic Milestone with European Approval of FemBloc®, the First Non-Surgical Permanent Birth Control

June 25, 2025

Femasys Names New Chief Commercial Officer to Drive Execution and Global Growth

June 17, 2025

Femasys Announces Partnership with Carolinas Fertility Institute, One of America’s Best Fertility Clinics, to Offer FemaSeed® in its More than 8 Locations

June 11, 2025

Femasys Announces Pricing of Underwritten Public Offering and Concurrent Private Placement with Gross Proceeds of $4.5 Million

May 30, 2025

Femasys Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

May 29, 2025

Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update

May 8, 2025

Older news releases →

Decks

The 5 newest of 14 decks. Every deck is listed under its year.